

31 July 2018
ASX Code: MXC

Global Neurology and Epilepsy Expert Joins MXC Medical Advisory Board

A
S
X

R
E
L
E
A
S
E

- Assoc. Professor Wendyl D’Souza joins the MXC Medical Advisory board to lead research and development into medicinal cannabis treatments for Epilepsy and other neurological disorders
- Assoc. Professor D’Souza is a renowned Consultant Neurologist and Epileptologist with over 15 years’ clinical experience researching new and emerging treatments for common neurological disorders within a rigorous scientific framework
- Assoc. Professor D’Souza is currently an Associate Professor in Neuroepidemiology & Health Services Research in the Department of Medicine, St Vincent’s Hospital, The University of Melbourne and Head of Epilepsy Services at St Vincent’s Hospital
- Assoc. Professor D’Souza is an Authorised Prescriber of Medicinal cannabis and treats over 3,000 patients with drug-resistant epilepsy from currently available treatments in Australia
- He has previously secured over \$15 million of funding for his research and will be instrumental in the development process of new MXC products

MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to welcome Assoc. Professor Wendyl D’Souza to the MGC Pharmaceuticals Medical Advisory board and to lead the Pharma division’s research and development projects in Australia and globally, effective 1 July 2018.

The addition of Assoc. Professor D’Souza further strengthens the Medical Advisory Board, and he will work alongside Professors Uri Kramer and David Neubauer to lead the Company’s research projects into cannabis based medicines as a treatment for neurological disorders. He will also lead a project into the further development and distribution of CannEpi™ and the next generation of medical cannabis medicines.

Assoc. Professor D’Souza is an Authorised Prescriber of medicinal cannabis and has over 3,000 registered patients with drug resistant epilepsy from currently available anti-epilepsy medications.

He has over 15 years' clinical experience leading ground-breaking projects into Neurological and Epileptic disorders in Australasia, and is an Associate Professor in Neuroepidemiology & Health Services Research in the Department of Medicine, St Vincent's Hospital, The University of Melbourne and Head of Epilepsy Services at St Vincent's Hospital.

During his longstanding career, he has won a number of prestigious national awards and fellowships recognising his pioneering work into Epilepsy and other neurological disorders. He has also been successful in securing a significant amount of external funding for his innovative projects which have included: FirstSparks, an app for the education and identification of epileptic seizures, the Tasmanian Epilepsy Register, a database of clinical epidemiology research and a system for self-managing Asthma which was adopted by the World Health Organisation and remains a 'blueprint' for adult asthma self-management care. Most recently in June 2018, in collaboration with Cochlear Ear, the Bionic Institute, Seer Medical, the University of Melbourne Department of Engineering and Neuro-Investments, he successfully secured venture capital to further test and develop the first in human diagnostic and therapeutic long-term EEG recording system available worldwide.

There is an estimated 240,000 people diagnosed with epilepsy in Australia each year and of those, 30% of are recognised as having drug-resistant (refractory) epilepsy, equating to a market of over 70,000 patients that would benefit from MXC's CannEpi™.

In 2017, MXC signed an exclusive supply agreement with leading Australian specialist pharmaceutical wholesaler and distributor HL Pharma Pty Ltd to bring CannEpi™ to the Australian market. Both Assoc. Professor D'Souza and HL Pharma will act as a means for providing patient access to CannEpi™.

The Company is actively working to develop new and innovative cannabis based medicines to treat a range of neurological and physical disorders and it is expected that Assoc. Professor D'Souza's considerable expertise will be instrumental in guiding the team in developing new and innovative cannabis based medicines.

Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented

"We are delighted to welcome Assoc. Professor D'Souza on board and expect his deep experience treating epilepsy and expertise in medical cannabis will be highly beneficial to the development of our pharmaceutical pipeline. Assoc. Professor D'Souza is a world renowned Neurology expert and we look forward to his input on the projects we are currently working on."

Assoc. Professor Wendyl D'Souza, Neurologist and Epileptologist commented

"I'm excited to be working with MGC Pharmaceutical, an innovative company with long-standing expertise in medicinal cannabis, raising future hope for patients with debilitating forms of epilepsy in Australia".

--Ends--

For further information, please contact:

Media Enquiries

Daniel Paperny
Media and Capital Partners
+61 433 339 454
daniel.paperny@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 6382 3390
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   